Gastric Cardia Cancer
Conditions
Keywords
Gastric Cardia Cancer, Single-Cell RNA Sequencing, Exosomes, Proteomics
Brief summary
This is an observational study with a case control design. This study included patients with gastric cancer confirmed by pathological diagnosis of gastric tissue, and matched the control population according to age, gender, etc. In this study, researchers collected clinical information and multiple biological samples such as serum and tissue tissue from the study subjects. The researchers combined exosome sequencing, proteomics and single-cell RNA sequencing to explore the heterogeneity of cardia cancer, identify specific biomarkers and potential therapeutic targets for cardia cancer, and provide a basis for the development of new diagnostic tools and therapeutic strategies.
Interventions
OTHERDetection of biological samples based on exosome sequencing, proteomics and single-cell RNA sequencing
The researchers combined exosome sequencing, proteomics and single-cell RNA sequencing to explore the heterogeneity of cardia cancer, identify specific biomarkers and potential therapeutic targets for cardia cancer.
Sponsors
Qilu Hospital of Shandong University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Study population signing informed consent form * Age: 18 years old or older * The study population must underwent endoscopic examination and was confirmed by pathological diagnosis as gastric cancer: including high-level intraepithelial neoplasia, early gastric cancer, and advanced gastric cancer.
Exclusion criteria
* Those who have undergone gastrointestinal surgery within the past 1 year; Patients who have undergone neoadjuvant chemotherapy and have developed tumors in the residual stomach after previous partial gastrectomy. * Those who have used proton pump inhibitors, antibiotics, probiotics, and prebiotics daily within the past month, and those who have recently received hormone therapy. * People with infectious diseases and other digestive system diseases that interfere with the experimental results, such as inflammatory bowel disease, irritable bowel syndrome, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differential protein | 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Key miRNA | 10 months | — |
| Differential cell subsets | 12 months | Differential cell subsets between cardiac cancer tissue and normal tissue |
Countries
China
Contacts
CONTACTXiaoya Wang, Bachelor
Outcome results
None listed